Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
FPRX's Cash-to-Debt is ranked higher than
76% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. FPRX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
FPRX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.80
FPRX's Equity-to-Asset is ranked higher than
78% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FPRX: 0.80 )
Ranked among companies with meaningful Equity-to-Asset only.
FPRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63  Med: 0.71 Max: 0.87
Current: 0.8
-2.63
0.87
Interest Coverage No Debt
FPRX's Interest Coverage is ranked higher than
70% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. FPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
FPRX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 5.40
Beneish M-Score: 1.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -442.46
FPRX's Operating Margin % is ranked lower than
64% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. FPRX: -442.46 )
Ranked among companies with meaningful Operating Margin % only.
FPRX' s Operating Margin % Range Over the Past 10 Years
Min: -442.46  Med: -195.38 Max: 75.56
Current: -442.46
-442.46
75.56
Net Margin % -408.42
FPRX's Net Margin % is ranked lower than
64% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. FPRX: -408.42 )
Ranked among companies with meaningful Net Margin % only.
FPRX' s Net Margin % Range Over the Past 10 Years
Min: -408.42  Med: -194.6 Max: 65.73
Current: -408.42
-408.42
65.73
ROE % -40.05
FPRX's ROE % is ranked higher than
55% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. FPRX: -40.05 )
Ranked among companies with meaningful ROE % only.
FPRX' s ROE % Range Over the Past 10 Years
Min: -52.26  Med: -15.93 Max: 96.31
Current: -40.05
-52.26
96.31
ROA % -34.25
FPRX's ROA % is ranked higher than
54% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. FPRX: -34.25 )
Ranked among companies with meaningful ROA % only.
FPRX' s ROA % Range Over the Past 10 Years
Min: -53.75  Med: -22.36 Max: 70.93
Current: -34.25
-53.75
70.93
ROC (Joel Greenblatt) % -1334.42
FPRX's ROC (Joel Greenblatt) % is ranked lower than
68% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. FPRX: -1334.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
FPRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1846.49  Med: -624.88 Max: 6887.63
Current: -1334.42
-1846.49
6887.63
3-Year Revenue Growth Rate -23.00
FPRX's 3-Year Revenue Growth Rate is ranked lower than
74% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. FPRX: -23.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
FPRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -46.5 Max: 19
Current: -23
0
19
3-Year EBITDA Growth Rate -10.40
FPRX's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. FPRX: -10.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
FPRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -5.2 Max: -10.4
Current: -10.4
3-Year EPS without NRI Growth Rate -22.40
FPRX's 3-Year EPS without NRI Growth Rate is ranked lower than
74% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. FPRX: -22.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
FPRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -11.2 Max: -22.4
Current: -22.4
» FPRX's 30-Y Financials

Financials (Next Earnings Date: 2018-02-23)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

FPRX Guru Trades in Q4 2016

Jim Simons Sold Out
John Hussman 115,000 sh (-8.00%)
Joel Greenblatt 11,150 sh (-16.92%)
Paul Tudor Jones 5,123 sh (-22.38%)
» More
Q1 2017

FPRX Guru Trades in Q1 2017

Jim Simons 462,901 sh (New)
Steven Cohen 19,569 sh (New)
Paul Tudor Jones 8,033 sh (+56.80%)
Joel Greenblatt Sold Out
John Hussman Sold Out
» More
Q2 2017

FPRX Guru Trades in Q2 2017

Paul Tudor Jones 11,999 sh (+49.37%)
Steven Cohen Sold Out
Jim Simons 431,500 sh (-6.78%)
» More
Q3 2017

FPRX Guru Trades in Q3 2017

Steven Cohen 62,982 sh (New)
Paul Tudor Jones 10,133 sh (-15.55%)
Jim Simons 70,700 sh (-83.62%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:FPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-03-31 Sold Out 0.01%$34.89 - $52.15 $ 26.99-39%0
Joel Greenblatt 2016-12-31 Reduce -16.92%$46.03 - $60.89 $ 26.99-49%11,150
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:002022, NAS:ZLAB, NAS:ANAB, NAS:MYOK, NAS:DVAX, OCSE:BAVA, NAS:INVA, XBRU:ABLX, SHSE:603718, XSWX:SFZN, NAS:ACOR, SZSE:000403, SZSE:002872, NYSE:CO, XPAR:ALCLS, SHSE:600200, XPAR:DBV, XTER:BIO3, SHSE:603896, SZSE:300204 » details
Traded in other countries:5P8.Germany,
Headquarter Location:USA
Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases.

Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company's technology.

Top Ranked Articles about Five Prime Therapeutics Inc

Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Five Prime Announces Third Quarter 2017 Results and Provides Business Update
Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155
Five Prime Therapeutics Announces Appointment of Aron Knickerbocker as CEO Effective January 1, 2018
Five Prime Therapeutics to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 6
Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
Five Prime Therapeutics to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Five Prime Presents Preclinical Research Data on Novel B7-H4 Therapeutic Antibody at ESMO 2017 Congress

Ratios

vs
industry
vs
history
PB Ratio 2.64
FPRX's PB Ratio is ranked higher than
55% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. FPRX: 2.64 )
Ranked among companies with meaningful PB Ratio only.
FPRX' s PB Ratio Range Over the Past 10 Years
Min: 1.77  Med: 3.27 Max: 8.42
Current: 2.64
1.77
8.42
PS Ratio 21.69
FPRX's PS Ratio is ranked lower than
70% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. FPRX: 21.69 )
Ranked among companies with meaningful PS Ratio only.
FPRX' s PS Ratio Range Over the Past 10 Years
Min: 0.99  Med: 13.44 Max: 50.54
Current: 21.69
0.99
50.54
EV-to-EBIT -3.03
FPRX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. FPRX: -3.03 )
Ranked among companies with meaningful EV-to-EBIT only.
FPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.8  Med: -4.6 Max: 4.6
Current: -3.03
-13.8
4.6
EV-to-EBITDA -3.07
FPRX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. FPRX: -3.07 )
Ranked among companies with meaningful EV-to-EBITDA only.
FPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.2  Med: -4.75 Max: 4.5
Current: -3.07
-14.2
4.5
EV-to-Revenue 13.32
FPRX's EV-to-Revenue is ranked lower than
64% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. FPRX: 13.32 )
Ranked among companies with meaningful EV-to-Revenue only.
FPRX' s EV-to-Revenue Range Over the Past 10 Years
Min: -4.9  Med: 12.65 Max: 38.4
Current: 13.32
-4.9
38.4
Current Ratio 7.29
FPRX's Current Ratio is ranked higher than
81% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. FPRX: 7.29 )
Ranked among companies with meaningful Current Ratio only.
FPRX' s Current Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.01 Max: 11.6
Current: 7.29
1.96
11.6
Quick Ratio 7.29
FPRX's Quick Ratio is ranked higher than
81% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. FPRX: 7.29 )
Ranked among companies with meaningful Quick Ratio only.
FPRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.96  Med: 8.01 Max: 11.6
Current: 7.29
1.96
11.6
Days Sales Outstanding 46.02
FPRX's Days Sales Outstanding is ranked higher than
69% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. FPRX: 46.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
FPRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.9  Med: 7.81 Max: 102.62
Current: 46.02
3.9
102.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.80
FPRX's 3-Year Average Share Buyback Ratio is ranked lower than
62% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. FPRX: -17.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FPRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -179.4  Med: -71.4 Max: 0
Current: -17.8
-179.4
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.04
FPRX's Price-to-Net-Cash is ranked higher than
74% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. FPRX: 3.04 )
Ranked among companies with meaningful Price-to-Net-Cash only.
FPRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 3.71 Max: 7.44
Current: 3.04
2.69
7.44
Price-to-Net-Current-Asset-Value 2.89
FPRX's Price-to-Net-Current-Asset-Value is ranked higher than
75% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. FPRX: 2.89 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
FPRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.62  Med: 3.49 Max: 7.24
Current: 2.89
2.62
7.24
Price-to-Tangible-Book 2.65
FPRX's Price-to-Tangible-Book is ranked higher than
65% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. FPRX: 2.65 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
FPRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.5  Med: 3.37 Max: 6.87
Current: 2.65
2.5
6.87
Price-to-Median-PS-Value 1.61
FPRX's Price-to-Median-PS-Value is ranked lower than
88% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. FPRX: 1.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
FPRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 0.97 Max: 3.38
Current: 1.61
0.11
3.38
Earnings Yield (Greenblatt) % -33.23
FPRX's Earnings Yield (Greenblatt) % is ranked lower than
66% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. FPRX: -33.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
FPRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -38.7  Med: -11.65 Max: 70.3
Current: -33.23
-38.7
70.3

More Statistics

Revenue (TTM) (Mil) $34.55
EPS (TTM) $ -5.07
Beta4.93
Short Percentage of Float9.72%
52-Week Range $21.41 - 60.98
Shares Outstanding (Mil)28.93

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 46 150 162 230
EPS ($) -5.50 -2.92 -2.93 -1.80
EPS without NRI ($) -5.50 -2.92 -2.93 -1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 22
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}